<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65495">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968538</url>
  </required_header>
  <id_info>
    <org_study_id>2009-096</org_study_id>
    <nct_id>NCT01968538</nct_id>
  </id_info>
  <brief_title>Prostate Metabolomic Study</brief_title>
  <official_title>A Pilot Study to Establish a Standardized Protocol for Omic Analysis of Patients With Clinically Localized Prostate Cancer Receiving Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or
      hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances
      in omic analysis may offer additional information to the physician about prognosis and
      radiation response. We propose to establish a protocol to incorporate omic analysis into the
      evaluation and treatment of patients with prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>molecular changes in biofluid</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer Patients</arm_group_label>
    <description>Prostate cancer patients who underwent radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>age-matched male who has no known prostate cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <arm_group_label>Prostate Cancer Patients</arm_group_label>
    <other_name>Prostate stereotactic body radiation therapy (SBRT) and intensive modulated radiation therapy (IMRT) or the combination of both (boost)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimen:For future Research   Optional  Destruction if requested  identifiable Urine
             yes	       no	             yes	     no Sputum	              yes	       no
       yes	     no Blood	              yes	       no	             yes	     no
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        200 prostate cancer patients vs. 200 healthy men
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males who are older than 18 years old,

          -  with clinically localized prostate cancer

          -  are receiving radiation therapy

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leonard N Chen, MD,PhD</last_name>
    <phone>202-444-3068</phone>
    <email>lnc@georgetown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard N Chen, MD,PhD</last_name>
      <phone>202-444-3068</phone>
      <email>lnc@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Sean P Collins, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
